Key Highlights
- ALLR reported a Q3 net loss of US$6,200 thousand versus US$2,806 thousand a year earlier.
- Research and development expenses were US$4,219 thousand versus US$1,203 thousand.
- A one-time US$3.2 million Phase 3 drug Manufacturing expense was recognized on delivery.
- Cash and restricted cash were US$24.1 million, of which US$10.0 million is restricted.
ALLR filed its Quarterly Report for the three and nine months ended September 30, 2026, on November 13, 2026. Total Revenue was US$5 thousand, all license revenue, with none in the third quarter of 2025. For the nine months, license revenue was US$30 thousand, from the license of Drug Response Predictor testing services.
Research and development expenses were US$4,219 thousand versus US$1,203 thousand, an increase of US$3.0 million that the company attributed to Phase 3 drug manufacturing costs and continuation of the Phase 2 clinical trial of stenoparib. A one-time expense of US$3.2 million for manufacturing of Phase 3 drug was recognized when the drug was delivered.
Operating Expenses, Other Items and Net Loss
General and administrative expenses were US$1,293 thousand versus US$1,315 thousand, which the company tied to a reduction in legal fees. Total operating expenses were US$5,512 thousand versus US$2,518 thousand, and the loss from operations was US$(5,507) thousand versus US$(2,518) thousand.
Interest income was US$205 thousand versus US$187 thousand, and interest expense was US$(1,012) thousand versus US$(57) thousand. The company attributed the interest expense and a US$136 thousand change in Fair Value of Warrant and derivative items primarily to the March 2026 issuance of promissory notes to Streeterville. Foreign exchange loss was US$(22) thousand versus US$(418) thousand. Total other expense, net, was US$(693) thousand versus US$(288) thousand, and net loss was US$(6,200) thousand versus US$(2,806) thousand.
For the nine months, operating expenses were US$10,896 thousand versus US$9,687 thousand, and net loss was US$(12,355) thousand versus US$(7,858) thousand.
Financing Agreements, Cash and Laboratory Certification
At September 30, the company had US$24.1 million in cash and restricted cash and an accumulated Deficit of US$142.6 million, of which US$10.0 million of cash is restricted to secure the B Note. It said operations have been financed primarily through convertible promissory notes and the sale of securities, and that no Equity sales or financing transactions took place in the third quarter, apart from US$0.2 million of common stock issued as a payment for debt.
On January 28, 2026, the company entered a Common Stock Purchase Agreement with Tumim Stone Capital LLC, allowing it to sell up to US$6.0 million of newly issued shares. On March 2, 2026, it entered a Note Purchase Agreement with Streeterville Capital, LLC, issuing a US$10.0 million unsecured note and a US$10.0 million secured note, with monthly cash redemptions of up to US$250,000 available to the holder beginning six months after issuance. The company said its existing cash and restricted cash may not be sufficient to fund operations through at least the next twelve months from the date of the report, and that it is pursuing additional financing.
On July 7, 2026, the company announced CLIA certification for its Horsholm, Denmark laboratory, which it said supports in-house testing for the acceleration of stenoparib toward FDA registration.
Quarter in Review: Stenoparib Spending and Funding Position
ALLR's third quarter combined a net loss of US$6,200 thousand with a one-time Phase 3 manufacturing expense for stenoparib, a PARP and tankyrase inhibitor developed with its Drug Response Predictor platform. The company reported cash and restricted cash of US$24.1 million, an equity line of up to US$6.0 million, and US$20.0 million of promissory notes issued in March 2026.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...